JCR Pharmaceuticals Co., Ltd. (TYO:4552)
Japan · Delayed Price · Currency is JPY 499.00
+6.00 (1.22%)
Nov 13, 2026, 3:25 PM JST
JCR Pharmaceuticals Employees
JCR Pharmaceuticals had 985 employees as of March 31, 2026. The number of employees decreased by 2 or 0.20% compared to the previous year. That makes JCR Pharmaceuticals the 15,011th largest employer in the world and 1,573rd in Japan.
Employees
985
Change (1Y)
-2
Growth (1Y)
-0.20%
Revenue / Employee
39.52M JPY
Profits / Employee
-3.49M JPY
Market Cap
61.00B
Employees Chart
| Date | Employees | Change (1Y) | Growth (1Y) |
|---|---|---|---|
| Mar 31, 2026 | 985 | -2 | -0.20% |
| Mar 31, 2025 | 987 | 53 | 5.67% |
| Mar 31, 2024 | 934 | 55 | 6.26% |
| Mar 31, 2023 | 879 | 63 | 7.72% |
| Mar 31, 2022 | 816 | 84 | 11.48% |
| Mar 31, 2021 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Related Stocks
| Company Name | Employees |
|---|---|
| Takeda Pharmaceutical Company | 47,029 |
| Otsuka Holdings | 37,758 |
| HOYA Corporation | 37,752 |
| Chugai Pharmaceutical | 5,104 |
| Charm Care | 2,546 |
| KYORIN Pharmaceutical | 1,982 |
| ASKA Pharmaceutical Holdings | 1,611 |
| Medley | 1,511 |
JCR Pharmaceuticals News
- 4 weeks ago - JCR Pharmaceuticals Receives Marketing Authorization in Kuwait for IZCARGO™, a Blood-Brain Barrier-Penetrating Enzyme Replacement Therapy for Hunter Syndrome - Business Wire
- 6 weeks ago - Italfarmaco and JCR Pharmaceuticals Enter into Exclusive License Agreement for the Development and Potential Commercialization of Novel Investigational Therapy for Hunter Syndrome in the United States, Europe, and Latin America - Business Wire
- 6 weeks ago - JCR Pharmaceuticals Receives Orphan Drug Designation from the Ministry of Health, Labour and Welfare of Japan for Givinostat for Duchenne Muscular Dystrophy - Business Wire
- 2 months ago - MEDIPAL HOLDINGS CORPORATION and JCR Pharmaceuticals Dose First Patient in Global Phase I/II Trial of JR-446 for Mucopolysaccharidosis Type IIIB - Business Wire
- 3 months ago - JCR Pharmaceuticals Receives Marketing Authorization in the United Arab Emirates for IZCARGO™, a Blood-Brain Barrier-Penetrating Enzyme Replacement Therapy for Hunter Syndrome - Business Wire
- 5 months ago - JCR Pharmaceuticals Announces That Acumen Pharmaceuticals Has Exercised its Exclusive Option to Develop Therapeutic Candidates for Alzheimer's Disease, Enabled by J-Brain Cargo® Technology Platform - Business Wire
- 5 months ago - JCR Pharmaceuticals' Research Presentations at the 18th International Symposium on MPS and Related Lysosomal Diseases 2026 Showcase Data from Its Investigational Treatments for Lysosomal Storage Disorders - Business Wire
- 5 months ago - JCR Pharmaceuticals to Present at the 18th International Symposium on MPS and Related Lysosomal Diseases 2026 - Business Wire